<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report on a nested case-control study with 328 cases with second malignant <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (SMN) following <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e> and 639 matched controls based on the German <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">Childhood Cancer</z:e> Registry </plain></SENT>
<SENT sid="1" pm="."><plain>In the adjusted overall analysis, the odds ratio (OR) for SMN following any radiotherapy or chemotherapy is 2.1 [95% confidence interval (CI): 1.8-3.3] and 1.8 (95% CI: 0.98-3.1), respectively </plain></SENT>
<SENT sid="2" pm="."><plain>The strongest effect is seen for <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (OR=2.0, 95% CI: 1.2-3.3) </plain></SENT>
<SENT sid="3" pm="."><plain>The risk of SMN after <z:hpo ids='HP_0001909'>leukemia</z:hpo> is pronounced for <z:chebi fb="0" ids="35221">antimetabolites</z:chebi> (OR=17.2, 95% CI: 1.7-177) and asparaginase (OR=4.3, 95% CI: 1.7-11.0) </plain></SENT>
<SENT sid="4" pm="."><plain>Following <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, the greatest effect is seen for <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> derivatives (OR=4.1, 95% CI: 1.7-10.1) </plain></SENT>
<SENT sid="5" pm="."><plain>For <z:chebi fb="0" ids="48120">anthracyclines</z:chebi>, a decreased risk is observed (OR=0.3, 95% CI: 0.1-0.6) </plain></SENT>
<SENT sid="6" pm="."><plain>Secondary <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> are mainly associated with radiotherapy (OR=4.5, 95% CI: 2.5-8.0), especially secondary <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> are mainly associated with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (OR=8.5, 95% CI: 0.97-74.8), asparaginase (OR=6.8, 95% CI: 2.3-20.6), and <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> derivatives (OR=4.5, 95% CI: 1.5-13.6) </plain></SENT>
<SENT sid="8" pm="."><plain>The observed risks are in many instances lower than the ones published in previous studies relating to earlier treatment eras of the <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary diseases</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>These differences may be attributed to less toxic but still effective treatment regimes but also to differences in the length of follow-up </plain></SENT>
</text></document>